The Department of Medicine at the Anschutz Medical Campus boasts top medical care for patients, as well as fellowships and endowments. The Grand Rounds Schedule includes all events for divisions under the department.

Education: MD

Medical School-University Central of Venezuela at Caracas. June 1998

Dr. Oton joined the faculty of the University of Colorado Denver in July 2007. She is  fluent in English and Spanish.

Research
Dr. Oton is focused on clinical cancer research. Her major interest is in new drug development in lung cancer and thoracic malignancies. Dr. Oton will be the principal investigator on several therapeutic trials at Denver Health and the University of Colorado. She started her research career at the University of Pittsburgh with a focus in the differences in lung cancer survival between pre-menopausal and post-menopausal women.

Publications
Owonikoko T, Ragin C, Belani CP, Oton A, Gooding W, Taioli E, Ramalingam S Lung Cancer in Elderly Patients: An Analysis of the SEER Database, Accepted for publication in Journal of Clinical Oncology, August 2007

Feng R, Oton A, Mapara M, Anderson G, Belani C, Lentzsch S. The Histone Deacetylase Inhibitor, PXD101, potentiates bortezomib-induced and anti-multiple myeloma effect by Induction of Oxidative Stress and DNA Damage. Br J of Haematology November 2007, 139(3):385-397

Oton A, Hong W, Melhem M, George D, Foon K, Ghobrial IM. Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders, BCL2 as Poor Prognostic Marker. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I (supplement). June 2007, 25(18S): 8073

Oton A, Belani C, Siegfried J, Ramalingam S. Comparison of Survival for Lung Cancer between Premenopausal and Postmenopausal Women: An Analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. 2006 ASCO Annual Meeting, JCO.